People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Chronic kidney disease affects about 37 million adults in the United States and is expected to rise. It is a common ...

The latest semaglutide (Ozempic; Novo Nordisk) approval is set to tackle a major need for patients with both type 2 diabetes ...

The dose of semaglutide was gradually increased up to 1 mg or the maximum tolerated dose. During the last 4 weeks of the 15, participants used a research-created automated insulin pump.

In the ongoing quest to expand semaglutide ... 1's market position, Novo Nordisk is rolling out new data on a higher-dose injection in obesity. In the phase 3b STEP UP study, an experimental 7.2 ...

The dose of semaglutide was gradually increased up to 1 mg or the maximum tolerated dose. During the last 4 weeks of the 15, participants used a research-created automated insulin pump.